Ubs Group Ag Ligand Pharmaceuticals Inc Call Options Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 13, 2021	SELL	$113.03 - $155.64 $791,210 - $1.09 Million	-7,000 Reduced 43.75%	9,000 $1.18 Million
Q1 2021 May 12, 2021	BUY	$99.52 - $215.83 $1.07 Million - $2.33 Million	10,800 Added 207.69%	16,000 $2.44 Million
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $474,668 - $671,616	-5,300 Reduced 50.48%	5,200 $496,000
Q1 2020 May 01, 2020	SELL	$63.37 - $107.88 $3.14 Million - $5.34 Million	-49,500 Reduced 82.5%	10,500 $764,000
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $4.22 Million - $4.94 Million	43,500 Added 263.64%	60,000 $6.26 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $1.42 Million - $1.98 Million	16,500 New	16,500 $1.64 Million

256

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.